Insider trade

Director sold ~$570K of REGN shares in the open market

Traded Nov 20, 2025 · Filed Nov 24, 2025

~$570K
Reported value · 760 sh @ $750.00: 1,548
Holds after · shares reported: -0.3%
stock since the trade · S&P 500 +17.1%, $737.00 → $734.81 on Oct 1

Why it stands out

A board member of Regeneron Pharmaceuticals sold $570K of Regeneron Pharmaceuticals shares. It was planned long ago, so it says very little.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Nov 20, 2025
Reporting period: Not applicable
Filed with the SEC: Nov 24, 2025

Director$500K–$1MPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$570,000

Shares × reported transaction price

Timing vs results

23 days after results of Oct 28, 2025, 53 days before results of Jan 12, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $737.00 on Nov 20, 2025, 53% above its 52-week low and 6% below its high, after a 29% rise over the previous 30 trading days

52-week range $483.07 (Jun 5, 2025) to $788.00 (Dec 9, 2024), 83% of the way up, from 250 adjusted closes. 30 trading days earlier: $569.90 on Oct 9, 2025. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Jan 7, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.

In re Regeneron Pharmaceuticals, Inc. Securities Litigation, docket 1:25-cv-00145, via CourtListener (court records). Nature of suit 850, company named as first defendant

FDA decision near the trade

FDA approved Eylea HD on Nov 19, 2025, 1 day before this trade.

New use approved (efficacy supplement). Active ingredient: Aflibercept. From openFDA. Dates only; no link between the two is implied